Literature DB >> 11063078

Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients.

S Józwiak1, R A Schwartz, C K Janniger, J Bielicka-Cymerman.   

Abstract

The Tuberous Sclerosis Complex 1998 Consensus Conference clinical criteria represent an important advance in the diagnosis of tuberous sclerosis complex. Since many findings regarded as highly specific for tuberous sclerosis complex are not apparent until late childhood or adulthood, refinements by age may prove of value. We have stratified 106 children into five age groups (0 to 2 years of age, above 2 to 5 years, above 5 to 9 years, above 9 to 14 years, and above 14 to 18 years). Physicians should be alerted as to the frequency of the criteria in different stages of children.

Entities:  

Mesh:

Year:  2000        PMID: 11063078     DOI: 10.1177/088307380001501003

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  44 in total

Review 1.  α-[¹¹C]-methyl-L-tryptophan PET for tracer localization of epileptogenic brain regions: clinical studies.

Authors:  Ajay Kumar; Eishi Asano; Harry T Chugani
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

2.  Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference.

Authors:  Hope Northrup; Darcy A Krueger
Journal:  Pediatr Neurol       Date:  2013-10       Impact factor: 3.372

Review 3.  New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex.

Authors:  Hilaire C Lam; Julie Nijmeh; Elizabeth P Henske
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

Review 4.  [Hereditary tumor syndromes in neuropathology].

Authors:  C Mawrin
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

5.  Clinical Characteristics of Connective Tissue Nevi in Tuberous Sclerosis Complex With Special Emphasis on Shagreen Patches.

Authors:  Michelle A Bongiorno; Neera Nathan; Oyetewa Oyerinde; Ji-An Wang; Chyi-Chia Richard Lee; G Thomas Brown; Joel Moss; Thomas N Darling
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

6.  mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis.

Authors:  Chunjia Li; Hongyu Chen; Zhou Lan; Shaozong He; Rongrong Chen; Fang Wang; Zhibo Liu; Kai Li; Lili Cheng; Ye Liu; Kun Sun; Xiaofeng Wan; Xinxin Chen; Haiyong Peng; Li Li; Yanjun Zhang; Yanling Jing; Min Huang; Yanan Wang; Yan Wang; Jiandong Jiang; Xiaojun Zha; Ligong Chen; Hongbing Zhang
Journal:  Cell Death Differ       Date:  2019-02-13       Impact factor: 15.828

7.  Factors affecting epilepsy prognosis in patients with tuberous sclerosis.

Authors:  Gülen Gül Mert; Şakir Altunbaşak; Özlem Hergüner; Faruk İncecik; Hilal Cansever Övetti; Neslihan Özcan; Duygu Kuşçu; İlker Ünal
Journal:  Childs Nerv Syst       Date:  2019-01-23       Impact factor: 1.475

Review 8.  Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.

Authors:  S Brakemeier; F Bachmann; K Budde
Journal:  Pediatr Nephrol       Date:  2016-09-01       Impact factor: 3.714

9.  Assessment of tumors in children with tuberous sclerosis: a single centre's experience.

Authors:  Suna Emir; Şadan Hacısalihoğlu; Derya Özyörük; Filiz Ekici; Aydan Değerliyurt; Alev Güven; İlker Çetin
Journal:  Turk Pediatri Ars       Date:  2017-03-01

10.  Brain MR spectroscopic abnormalities in "MRI-negative" tuberous sclerosis complex patients.

Authors:  William E Wu; Ivan I Kirov; Assaf Tal; James S Babb; Sarah Milla; Joseph Oved; Howard L Weiner; Orrin Devinsky; Oded Gonen
Journal:  Epilepsy Behav       Date:  2013-03-22       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.